SCHEMBL17682016

SCHEMBL17682016

CC(=O)c1ccc(C)cc1C1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP2A6 P11509 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP2D6 P10635 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
CHRNB2 P17787 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728643 0.93 PTGDR2 (0.51) DRD2DRD4DRD3PTGDR2DDB1
SCHEMBL27436953 0.87 PTGDR2 (0.44) DRD2DRD4DRD3PTGDR2TAS1R3
SCHEMBL16421197 0.85 CSNK2A1 (0.48) DRD2DRD4DRD3PTGDR2KDM4C
SCHEMBL30410929 0.85 CSNK2A1 (0.48) DRD2DRD4DRD3PTGDR2KDM4C
SCHEMBL2946563 0.84 PTGDR2 (0.42) DRD2DRD4DRD3PTGDR2TAS1R3
Hydrochloric Acid SCHEMBL5614018 0.82 PTGDR2 (0.41) DRD2DRD4DRD3PTGDR2TAS1R3
SCHEMBL16126359 0.81 PTGDR2 (0.40) DRD2DRD4DRD3PTGDR2TAS1R3
SCHEMBL16951724 0.81 PDK2 (0.46) PTGDR2TAS1R3TAS1R1TAS1R2NPC1
SCHEMBL17679285 0.81 PTGDR2 (0.40) DRD2DRD4DRD3PTGDR2TAS1R3
SCHEMBL17682015 0.80 PTGDR2 (0.42) PTGDR2HCRTR1HCRTR2HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR2 DRD2 168/4885DRD4 374/4885DRD3 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.